Welcome to our dedicated page for Irhythm Technologies SEC filings (Ticker: IRTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC documents from iRhythm Technologies don’t just recount earnings—they weave together reimbursement rulings, FDA study updates, and device-level production metrics that can shift Zio patch economics overnight. For investors, pulling the one sentence about CMS pricing from a 250-page 10-K or tracking day-to-day insider sales feels daunting.
Stock Titan solves that complexity. Our AI reads every iRhythm quarterly earnings report 10-Q filing, each iRhythm 8-K material event, and flags changes in plain English. Want iRhythm insider trading Form 4 transactions within minutes? You’ll see alerts the moment the Form 4 hits EDGAR, complete with contextual charts. Need an iRhythm annual report 10-K simplified or a quick iRhythm earnings report filing analysis? Our summaries spotlight Zio XT volume, average selling price shifts, and R&D spend so you can focus on decisions instead of footnotes.
Common investor questions are answered up front:
- iRhythm Form 4 insider transactions real-time
- iRhythm proxy statement executive compensation details
- understanding iRhythm SEC documents with AI
Beyond speed, our platform ties each disclosure to what truly moves the stock: hospital adoption rates, Medicare billing codes, and manufacturing scale. Drill into an iRhythm executive stock transactions Form 4 to see how trades align with new Zio AT rollouts, or compare segment margins across quarters without combing through PDFs. With real-time updates, complete filing coverage, and AI-powered plain-language explanations, iRhythm SEC filings explained simply becomes more than a promise—it’s the workflow that lets you act before the market does.
Form 3/A overview: iRhythm Technologies, Inc. (IRTC) filed an amended Form 3 for newly appointed Chief Technology Officer Brian Lee Lawrence. The amendment, dated 06/27/2025, corrects the original 04/21/2025 filing by attaching the Power of Attorney that was previously omitted.
Key points for investors:
- No securities owned: The report states that Mr. Lawrence currently holds zero shares or derivative securities of IRTC.
- Administrative nature: No changes to capital structure, operations, or financial outlook are disclosed; the sole purpose is to provide the missing document.
- Insider alignment: The absence of ownership may indicate limited immediate equity alignment between the CTO and shareholders, although incentive grants can follow after employment begins.
This filing is largely procedural and does not contain material financial information or signal any strategic shift for iRhythm.
Form 4 overview: iRhythm Technologies (IRTC) Chief Financial Officer Daniel G. Wilson disclosed the sale of 3,000 common shares on 06/23/2025 at $150 per share, generating approximately $450,000 in proceeds.
Remaining ownership: After the transaction, Wilson directly owns 40,307 shares. No indirect holdings were reported.
Trade context: The filing states the sale was executed pursuant to a Rule 10b5-1 trading plan adopted on 11/14/2024, which can shield the insider from accusations of timing the market.
No derivative activity: Table II shows no option exercises, grants, or other derivative movements.
Investor takeaways: Insider sales can raise questions about management’s confidence, but the modest size relative to Wilson’s remaining stake and the pre-planned nature reduce negative interpretation. The transaction does not affect the company’s capital structure or operations but provides incremental insight into insider sentiment toward IRTC’s valuation around the $150 level.
iRhythm Technologies, Inc. (NASDAQ: IRTC) – Form 144 filing overview
On the latest Form 144 notice, insider Daniel Wilson has disclosed a proposed sale of 3,000 common shares of iRhythm Technologies. The sale will be executed through Morgan Stanley Smith Barney LLC on or about 23 June 2025. Based on the filing’s stated price, the transaction is valued at approximately $450,000.
iRhythm reports 31,925,267 shares outstanding; the proposed sale therefore equals roughly 0.009 % of the company’s issued shares. The shares being sold were originally acquired via company equity awards: 1,063 performance shares (27 Feb 2023), 970 restricted shares (1 Mar 2023) and 967 performance shares (27 Feb 2024).
The filing also lists insider sales during the previous three months: on 2 May 2025, Wilson sold 333 and 1,667 common shares for total gross proceeds of $250,000. The Form 144 certification states that the seller affirms no knowledge of undisclosed material adverse information at the time of filing.
Because the notice covers a relatively small portion of total shares outstanding and does not introduce new corporate information, the immediate market impact is expected to be limited; nevertheless, investors often track insider activity for signalling purposes.
iRhythm Technologies (NASDAQ: IRTC) has filed a Form 144 notice for a proposed sale of securities by an insider. The filing details planned sales of 936 shares of common stock with an aggregate market value of $140,400, to be executed through Morgan Stanley Smith Barney LLC on the NASDAQ exchange around June 23, 2025.
The securities were originally acquired as Restricted Stock from the issuer on March 1, 2025. The selling party, Chad Patterson, has conducted several previous transactions in the past 3 months totaling:
- 363 shares sold on June 10, 2025 ($54,450)
- 8,510 shares sold on May 2, 2025 ($1,025,897.50)
The total outstanding shares of iRhythm Technologies are reported at 31,925,267. This Form 144 filing indicates the seller's representation that they are not aware of any material adverse non-public information regarding the company's operations.
FAQ
What is the current stock price of Irhythm Technologies (IRTC)?
What is the market cap of Irhythm Technologies (IRTC)?
What is iRhythm Technologies Inc?
How does the Zio System work?
What makes iRhythm's technology different from traditional cardiac monitoring methods?
What role does artificial intelligence play in iRhythm's approach?
How does iRhythm enhance clinical efficiency?
What conditions can iRhythm's monitoring services help detect?
How is iRhythm positioned within the global market?
What regulatory approvals has iRhythm achieved?
How does iRhythm integrate digital health tools in its services?
